Graphic Abstract

graphic
View largeDownload slide
Journal Section:
Research Article
Keywords:
Tumor heterogeneity, Volumetric parameters, Hybrid standardized uptake value thresholding method, Neuroendocrine neoplasms, 68Ga-DOTATATE

Introduction: The ability of PET/CT imaging to delineate neuroendocrine neoplasms (NENs) and predict prognosis in affected patients is often compromised by substantial uptake heterogeneity. We hereby proposed a hybrid standardized uptake value (SUV) thresholding algorithm to extract volumetric parameters from somatostatin receptor (SSTR) PET/CT imaging and investigate their prognostic performance in patients with 68Ga-DOTATATE-avid stage IV NENs. Methods: For 38 retrospectively enrolled patients, we used either fixed SUV thresholding of normal liver parenchyma (method A), 41% of the SUVmax for each lesion (method B), or a hybrid method (method A for liver metastases; fixed SUV threshold of normal bone for bone metastases; method B for primary tumors and other metastases) to quantify the whole-body SSTR-expressing tumor volume (SRETVwb) and total lesion SSTR expression (TLSREwb). Patient survival was also recorded and analyzed. Results: PET/CT images revealed heterogeneous uptake of 68Ga-DOTATATE at primary and metastatic sites. Progression-free survival (PFS) and overall survival (OS) were negatively correlated with the extent of liver or bone metastases (p < 0.05), but not significantly correlated with tumor grade or 18F-FDG PET/CT positivity. By the hybrid method, PFS was significantly shorter in patients with high SRETVwb, and OS was significantly shorter in those with high SRETVwb and TLSREwb (p < 0.05). However, when derived from method A or method B, neither SRETVwb nor TLSREwb could predict patient outcomes. Conclusion: Compared with other methods used in 68Ga-DOTATATE-avid stage IV NENs, our hybrid SUV thresholding method demonstrated robustness, with greater precision, reliability, and prognostic power.

Journal Section:
Research Article
Keywords:
Tumor heterogeneity, Volumetric parameters, Hybrid standardized uptake value thresholding method, Neuroendocrine neoplasms, 68Ga-DOTATATE
1.
Pavel
M
,
O’Toole
D
,
Costa
F
,
Capdevila
J
,
Gross
D
,
Kianmanesh
R
et al.
Vienna consensus conference p: ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site
.
Neuroendocrinology
.
2016
;
103
(
2
):
172
–
85
.
Google Scholar
 
2.
Bozkurt
MF
,
Virgolini
I
,
Balogova
S
,
Beheshti
M
,
Rubello
D
,
Decristoforo
C
et al.
Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA
.
Eur J Nucl Med Mol Imaging
.
2017
;
44
(
9
):
1588
–
601
.
Google Scholar
 
3.
Ambrosini
V
,
Campana
D
,
Polverari
G
,
Peterle
C
,
Diodato
S
,
Ricci
C
et al.
Prognostic value of 68Ga-DOTANOC PET/CT SUVmax in patients with neuroendocrine tumors of the pancreas
.
J Nucl Med
.
2015
;
56
(
12
):
1843
–
8
.
Google Scholar
 
4.
Sharma
P
,
Naswa
N
,
Kc
SS
,
Alvarado
LA
,
Dwivedi
AK
,
Yadav
Y
et al.
Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor
.
Eur J Nucl Med Mol Imaging
.
2014
;
41
(
12
):
2194
–
202
.
Google Scholar
 
5.
Eude
F
,
Guisier
F
,
Salaun
M
,
Thiberville
L
,
Pressat-Laffouilhere
T
,
Vera
P
et al.
Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab
.
Ann Nucl Med
.
2022
;
36
(
3
):
224
–
34
.
Google Scholar
 
6.
Pinochet
P
,
Texte
E
,
Stamatoullas-Bastard
A
,
Vera
P
,
Mihailescu
SD
,
Becker
S
.
Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin’s lymphoma
.
Sci Rep
.
2021
;
11
(
1
):
23195
.
Google Scholar
 
7.
Rocha
ALG
,
da Conceicao
MAM
,
da Cunha Sequeira Mano
FXP
,
Martins
HC
,
Costa
G
,
Dos Santos Oliveiros Paiva
BCB
et al.
Metabolic active tumour volume quantified on ([18]F)FDG PET/CT further stratifies TNM stage IV non-small cell lung cancer patients
.
J Cancer Res Clin Oncol
.
2021
;
147
(
12
):
3601
–
11
.
Google Scholar
 
8.
Albano
D
,
Bosio
G
,
Pagani
C
,
Re
A
,
Tucci
A
,
Giubbini
R
et al.
Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma
.
Eur J Nucl Med Mol Imaging
.
2019
;
46
(
1
):
87
–
96
.
Google Scholar
 
9.
Im
HJ
,
Pak
K
,
Cheon
GJ
,
Kang
KW
,
Kim
SJ
,
Kim
IJ
et al.
Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis
.
Eur J Nucl Med Mol Imaging
.
2015
;
42
(
2
):
241
–
51
.
Google Scholar
 
10.
Toriihara
A
,
Baratto
L
,
Nobashi
T
,
Park
S
,
Hatami
N
,
Davidzon
G
et al.
Prognostic value of somatostatin receptor expressing tumor volume calculated from (68)Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors
.
Eur J Nucl Med Mol Imaging
.
2019
;
46
(
11
):
2244
–
51
.
Google Scholar
 
11.
Tirosh
A
,
Papadakis
GZ
,
Millo
C
,
Hammoud
D
,
Sadowski
SM
,
Herscovitch
P
et al.
Prognostic utility of total 68Ga-DOTATATE-Avid tumor volume in patients with neuroendocrine tumors
.
Gastroenterology
.
2018
;
154
(
4
):
998
1008.e1
.
Google Scholar
 
12.
Reddy
RP
,
Ross Schmidtlein
C
,
Giancipoli
RG
,
Mauguen
A
,
LaFontaine
D
,
Schoder
H
et al.
The quest for an accurate functional tumor volume with 68Ga-DOTATATE PET/CT
.
J Nucl Med
.
2022
;
63
(
7
):
1027
–
32
.
Google Scholar
 
13.
Abdulrezzak
U
,
Kurt
YK
,
Kula
M
,
Tutus
A
.
Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors
.
Nucl Med Commun
.
2016
;
37
(
8
):
874
–
81
.
Google Scholar
 
14.
Ohlendorf
F
,
Henkenberens
C
,
Brunkhorst
T
,
Ross
TL
,
Christiansen
H
,
Bengel
FM
et al.
Volumetric 68Ga-DOTA-TATE PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with metastatic gastroenteropancreatic neuroendocrine tumors
.
Q J Nucl Med Mol Imaging
.
2022
;
66
(
4
):
361
–
71
.
Google Scholar
 
15.
Durmo
R
,
Filice
A
,
Fioroni
F
,
Cervati
V
,
Finocchiaro
D
,
Coruzzi
C
et al.
Predictive and prognostic role of pre-therapy and interim 68Ga-DOTATOC PET/CT parameters in metastatic advanced neuroendocrine tumor patients treated with PRRT
.
Cancers
.
2022
;
14
(
3
):
592
.
Google Scholar
 
16.
Thuillier
P
,
Liberini
V
,
Grimaldi
S
,
Rampado
O
,
Gallio
E
,
Santi
B
et al.
Prognostic value of whole-body PET volumetric parameters extracted from (68)Ga-DOTATOC PET/CT in well-differentiated neuroendocrine tumors
.
J Nucl Med
.
2022
;
63
(
7
):
1014
–
20
.
Google Scholar
 
17.
Carlsen
EA
,
Johnbeck
CB
,
Loft
M
,
Pfeifer
A
,
Oturai
P
,
Langer
SW
et al.
Semiautomatic tumor delineation for evaluation of (64)Cu-DOTATATE PET/CT in patients with neuroendocrine neoplasms: prognostication based on lowest lesion uptake and total tumor volume
.
J Nucl Med
.
2021
;
62
(
11
):
1564
–
70
.
Google Scholar
 
18.
Pauwels
E
,
Van Binnebeek
S
,
Vandecaveye
V
,
Baete
K
,
Vanbilloen
H
,
Koole
M
et al.
Inflammation-based index and (68)Ga-DOTATOC PET-derived uptake and volumetric parameters predict outcome in neuroendocrine tumor patients treated with (90)Y-DOTATOC
.
J Nucl Med
.
2020
;
61
(
7
):
1014
–
20
.
Google Scholar
 
19.
Hou
J
,
Yang
Y
,
Chen
N
,
Chen
D
,
Hu
S
.
Prognostic value of volume-based parameters measured by SSTR PET/CT in neuroendocrine tumors: a systematic review and meta-analysis
.
Front Med
.
2021
;
8
:
771912
.
Google Scholar
 
20.
Feijtel
D
,
Doeswijk
GN
,
Verkaik
NS
,
Haeck
JC
,
Chicco
D
,
Angotti
C
et al.
Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response
.
Theranostics
.
2021
;
11
:
491
–
505
.
Google Scholar
 
21.
Werner
RA
,
Ilhan
H
,
Lehner
S
,
Papp
L
,
Zsoter
N
,
Schatka
I
et al.
Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy
.
Mol Imaging Biol
.
2019
;
21
(
3
):
582
–
90
.
Google Scholar
 
22.
Graf
J
,
Pape
UF
,
Jann
H
,
Denecke
T
,
Arsenic
R
,
Brenner
W
et al.
Prognostic significance of somatostatin receptor heterogeneity in progressive neuroendocrine tumor treated with Lu-177 DOTATOC or Lu-177 DOTATATE
.
Eur J Nucl Med Mol Imaging
.
2020
;
47
(
4
):
881
–
94
.
Google Scholar
 
23.
Charoenpitakchai
M
,
Liu
E
,
Zhao
Z
,
Koyama
T
,
Huh
WJ
,
Berlin
J
et al.
In liver metastases from small intestinal neuroendocrine tumors, SSTR2A expression is heterogeneous
.
Virchows Arch
.
2017
;
470
(
5
):
545
–
52
.
Google Scholar
 
24.
Fonti
R
,
Panico
M
,
Pellegrino
S
,
Pulcrano
A
,
Vastarella
LA
,
Torbati
AHM
et al.
Heterogeneity of SSTR2 expression assessed by (68)Ga-DOTATOC PET/CT using coefficient of variation in patients with neuroendocrine tumors
.
J Nucl Med
.
2022
;
63
(
10
):
1509
–
14
.
Google Scholar
 
25.
Nagtegaal
ID
,
Odze
RD
,
Klimstra
D
,
Paradis
V
,
Rugge
M
WHO Classification of Tumours Editorial Board
et al.
The 2019 WHO classification of tumours of the digestive system
.
Histopathology
.
2020
;
76
(
2
):
182
–
8
.
Google Scholar
 
26.
Klimstra
DS
.
Pathology reporting of neuroendocrine tumors: essential elements for accurate diagnosis, classification, and staging
.
Semin Oncol
.
2013
;
40
(
1
):
23
–
36
.
Google Scholar
 
27.
Eisenhauer
EA
,
Therasse
P
,
Bogaerts
J
,
Schwartz
LH
,
Sargent
D
,
Ford
R
et al.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
.
Eur J Cancer
.
2009
;
45
(
2
):
228
–
47
.
Google Scholar
 
28.
Nioche
C
,
Orlhac
F
,
Boughdad
S
,
Reuze
S
,
Goya-Outi
J
,
Robert
C
et al.
LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity
.
Cancer Res
.
2018
;
78
(
16
):
4786
–
9
.
Google Scholar
 
29.
Shastry
M
,
Kayani
I
,
Wild
D
,
Caplin
M
,
Visvikis
D
,
Gacinovic
S
et al.
Distribution pattern of 68Ga-DOTATATE in disease-free patients
.
Nucl Med Commun
.
2010
;
31
(
12
):
1025
–
32
.
Google Scholar
 
30.
Budczies
J
,
Klauschen
F
,
Sinn
BV
,
Győrffy
B
,
Schmitt
WD
,
Darb-Esfahani
S
et al.
Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization
.
PLoS One
.
2012
;
7
(
12
):
e51862
.
Google Scholar
 
31.
Dasari
A
,
Shen
C
,
Halperin
D
,
Zhao
B
,
Zhou
S
,
Xu
Y
et al.
Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States
.
JAMA Oncol
.
2017
;
3
(
10
):
1335
–
42
.
Google Scholar
 
32.
Stotz
M
,
Eisner
F
,
Szkandera
J
,
Absenger
G
,
Kornprat
P
,
Lackner
C
et al.
Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series
.
J Clin Pathol
.
2013
;
66
(
9
):
753
–
7
.
Google Scholar
 
33.
Borbath
I
,
Garcia-Carbonero
R
,
Bikmukhametov
D
,
Jimenez-Fonseca
P
,
Castano
A
,
Barkmanova
J
et al.
The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms
.
Eur J Cancer
.
2022
;
168
:
80
–
90
.
Google Scholar
 
34.
Han
S
,
Lee
HS
,
Woo
S
,
Kim
TH
,
Yoo
C
,
Ryoo
BY
et al.
Prognostic value of 18F-FDG PET in neuroendocrine neoplasm: a systematic review and meta-analysis
.
Clin Nucl Med
.
2021
;
46
(
9
):
723
–
31
.
Google Scholar
 
35.
Binderup
T
,
Knigge
U
,
Johnbeck
CB
,
Loft
A
,
Berthelsen
AK
,
Oturai
P
et al.
18F-FDG PET is superior to WHO grading as a prognostic tool in neuroendocrine neoplasms and useful in guiding PRRT: a prospective 10-year follow-up study
.
J Nucl Med
.
2021
;
62
(
6
):
808
–
15
.
Google Scholar
 
36.
Bahri
H
,
Laurence
L
,
Edeline
J
,
Leghzali
H
,
Devillers
A
,
Raoul
JL
et al.
High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation
.
J Nucl Med
.
2014
;
55
(
11
):
1786
–
90
.
Google Scholar
 
37.
Chan
DL
,
Bernard
EJ
,
Schembri
G
,
Roach
PJ
,
Johnson
M
,
Pavlakis
N
et al.
High metabolic tumour volume on 18-fluorodeoxyglucose positron emission tomography predicts poor survival from neuroendocrine neoplasms
.
Neuroendocrinology
.
2020
110
11–12
950
8
.
Google Scholar
 
38.
Zhang
J
,
Liu
Q
,
Singh
A
,
Schuchardt
C
,
Kulkarni
HR
,
Baum
RP
.
Prognostic value of (18)F-FDG PET/CT in a large cohort of patients with advanced metastatic neuroendocrine neoplasms treated with peptide receptor radionuclide therapy
.
J Nucl Med
.
2020
;
61
(
11
):
1560
–
9
.
Google Scholar
 
39.
Kubota
K
,
Okasaki
M
,
Minamimoto
R
,
Miyata
Y
,
Morooka
M
,
Nakajima
K
et al.
Lesion-based analysis of (18)F-FDG uptake and (111)In-Pentetreotide uptake by neuroendocrine tumors
.
Ann Nucl Med
.
2014
;
28
(
10
):
1004
–
10
.
Google Scholar
 
40.
Eude
F
,
Toledano
MN
,
Vera
P
,
Tilly
H
,
Mihailescu
SD
,
Becker
S
.
Reproducibility of baseline tumour metabolic volume measurements in diffuse large B-cell LymphomA: is there a superior method
.
Metabolites
.
2021
;
11
(
2
):
72
.
Google Scholar
 
41.
Chen
L
,
Jumai
N
,
He
Q
,
Liu
M
,
Lin
Y
,
Luo
Y
et al.
The role of quantitative tumor burden based on ([68] Ga)Ga-DOTA-NOC PET/CT in well-differentiated neuroendocrine tumors: beyond prognosis
.
Eur J Nucl Med Mol Imaging
.
2023
;
50
(
2
):
525
–
34
.
Google Scholar
 
42.
Nuzzo
RL
.
Making continuous measurements into dichotomous variables
.
PM R
.
2019
;
11
(
10
):
1132
–
4
.
Google Scholar
 
43.
van Sluis
J
,
de Heer
EC
,
Boellaard
M
,
Jalving
M
,
Brouwers
AH
,
Boellaard
R
.
Clinically feasible semi-automatic workflows for measuring metabolically active tumour volume in metastatic melanoma
.
Eur J Nucl Med Mol Imaging
.
2021
;
48
(
5
):
1498
–
510
.
Google Scholar
 
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.